141 results
Page 2 of 8
6-K
EX-99.1
gfhxjl8uu7tivyb7fdn
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
74rc1x5ielfdu18zoje
6 Jul 23
Current report (foreign)
6:18am
6-K
ya1vi7r wi
28 Jun 23
Current report (foreign)
6:02am
6-K
EX-99.1
ekv4cz 074m
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
nc1u64m pvuf4zkd
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
1nn3fakci3sa4iabz
30 May 23
Current report (foreign)
6:11am
6-K
b5diikc2dftrj4
17 May 23
Current report (foreign)
6:02am
6-K
la1x1gywc07wv
11 May 23
Current report (foreign)
6:10am
6-K
anp4vo 3rys2w
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
49ka69 6iieukdes4
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
7lfvpb 31
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
d9a9xu dngd8ncv1ak1o
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
a4503tkpkmuxc
8 Dec 22
Current report (foreign)
6:46am
6-K
EX-99.1
7zal pzktxrchvd5g
30 Nov 22
Current report (foreign)
6:28am
6-K
apxr6g6jei2fc5
4 Nov 22
Current report (foreign)
6:01am
6-K
spir772v
27 Oct 22
Current report (foreign)
6:01am
6-K
EX-99.1
qjxpkjwfzpxhjm1fz
27 Oct 22
Current report (foreign)
6:01am
6-K
l7qdyoly
14 Oct 22
Current report (foreign)
7:36am
6-K
n8n45
4 Oct 22
Current report (foreign)
6:06am